Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine The ROPA-DOP Trial

被引:35
|
作者
Sharma, Kavita [1 ]
Vaishnav, Joban [1 ]
Kalathiya, Rohan [1 ]
Hu, Jiun-Ruey [1 ]
Miller, John [1 ]
Shah, Nishant [1 ]
Hill, Terence [1 ]
Sharp, Michelle [1 ]
Tsao, Allison [1 ]
Alexander, Kevin M. [1 ]
Gupta, Richa [1 ]
Montemayor, Kristina [1 ]
Kovell, Lara [1 ]
Chasler, Jessica E. [1 ]
Lee, Yizhen J. [1 ]
Fine, Derek M. [2 ]
Kass, David A. [1 ]
Weiss, Robert G. [1 ]
Thiemann, David R. [1 ]
Ndumele, Chiadi E. [1 ]
Schulman, Steven P. [1 ]
Russell, Stuart D. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD USA
关键词
acute decompensated heart failure; diuresis; dopamine; heart failure with preserved ejection fraction; worsening renal function; LOW-DOSE DOPAMINE; WORSENING RENAL-FUNCTION; FUROSEMIDE; DYSFUNCTION; PREVALENCE; INFUSION; EFFICACY; OUTCOMES; TRENDS;
D O I
10.1016/j.jchf.2018.04.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study sought to compare a continuous infusion diuretic strategy versus an intermittent bolus diuretic strategy, with the addition of low-dose dopamine (3 mg/kg/min) in the treatment of hospitalized patients with heart failure with preserved ejection fraction (HFpEF). BACKGROUND HFpEF patients are susceptible to development of worsening renal function (WRF) when hospitalized with acute heart failure; however, inpatient treatment strategies to achieve safe and effective diuresis in HFpEF patients have not been studied to date. METHODS In a prospective, randomized, clinical trial, 90 HFpEF patients hospitalized with acute heart failure were randomized within 24 h of admission to 1 of 4 treatments: 1) intravenous bolus furosemide administered every 12 h; 2) continuous infusion furosemide; 3) intermittent bolus furosemide with low-dose dopamine; and 4) continuous infusion furosemide with low-dose dopamine. The primary endpoint was percent change in creatinine from baseline to 72 h. Linear and logistic regression analyses with tests for interactions between diuretic and dopamine strategies were performed. RESULTS Compared to intermittent bolus strategy, the continuous infusion strategy was associated with higher percent increase in creatinine (continuous infusion: 16.01%; 95% confidence interval [CI]: 8.58% to 23.45% vs. intermittent bolus: 4.62%; 95% CI: -1.15% to 10.39%; p = 0.02). Low-dose dopamine had no significant effect on percent change in creatinine (low-dose dopamine: 12.79%; 95% CI: 5.66% to 19.92%, vs. no-dopamine: 8.03%; 95% CI: 1.44% to 14.62%; p = 0.33). Continuous infusion was also associated with greater risk of WRF than intermittent bolus (odds ratio [ OR]: 4.32; 95% CI: 1.26 to 14.74; p = 0.02); no differences in WRF risk were seen with low-dose dopamine. No significant interaction was seen between diuretic strategy and low-dose dopamine (p > 0.10). CONCLUSIONS In HFpEF patients hospitalized with acute heart failure, low-dose dopamine had no significant impact on renal function, and a continuous infusion diuretic strategy was associated with renal impairment. (Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction [ROPA-DOP]; NCT01901809) (C) 2018 by the American College of Cardiology Foundation.
引用
收藏
页码:859 / 870
页数:12
相关论文
共 50 条
  • [41] Spironolactone in patients with heart failure and preserved ejection fraction
    Nunez, J.
    Nunez, E.
    Sanchis, J.
    REVISTA CLINICA ESPANOLA, 2016, 216 (02): : 111 - 111
  • [42] Irbesartan in patients with heart failure and preserved ejection fraction
    Forman D.
    Gaziano J.M.
    Current Cardiovascular Risk Reports, 2009, 3 (5) : 311 - 312
  • [43] Spironolactone in patients with heart failure and preserved ejection fraction
    Sanchez-Sanchez, C.
    Mendoza-Ruiz de Zuazu, H. F.
    Formiga, F.
    Manzano, L.
    Ceresuela, L. M.
    Carrera-Izquierdo, M.
    Gonzalez Franco, A.
    Epelde-Gonzalo, F.
    Cerqueiro-Gonzalez, J. M.
    Montero-Perez-Barquero, M.
    REVISTA CLINICA ESPANOLA, 2015, 215 (06): : 301 - 307
  • [44] Treatment of patients with heart failure and preserved ejection fraction
    Deswal A.
    Bozkurt B.
    Current Treatment Options in Cardiovascular Medicine, 2008, 10 (6) : 516 - 528
  • [45] Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction
    Nanayakkara, Shane
    Patel, Hitesh C.
    Kaye, David M.
    CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2018, 12
  • [46] Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
    Poppe, Katrina K.
    Doughty, Robert N.
    HEART FAILURE CLINICS, 2014, 10 (03) : 503 - +
  • [47] Statins Beneficial for Heart Failure With Preserved Ejection Fraction But Not Heart Failure With Reduced Ejection Fraction?
    Ohte, Nobuyuki
    Little, William C.
    CIRCULATION JOURNAL, 2015, 79 (03) : 508 - 509
  • [48] Hypoxaemia in patients with heart failure and preserved ejection fraction
    Omar, Massar
    Omote, Kazunori
    Sorimachi, Hidemi
    Popovic, Dejana
    Kanwar, Ardaas
    Alogna, Alessio
    Reddy, Yogesh N. V.
    Lim, Kaiser G.
    Shah, Sanjiv J.
    Borlaug, Barry A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (09) : 1593 - 1603
  • [49] Management of patients with heart failure and preserved ejection fraction
    Jasinska-Piadlo, Alicja
    Campbell, Patricia
    HEART, 2023, 109 (11) : 874 - 883
  • [50] Prognosis for Patients With Heart Failure With Preserved Ejection Fraction
    Jacob, Javier
    Herrero, Pablo
    Martin-Sanchez, Francisco Javier
    Llorens, Pere
    Gil, Victor
    Miro, Oscar
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (03): : 300 - 301